September 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent
 

Tokyo, Jan 9, 2013 (JCN) - Chugai Pharmaceutical has granted Debiopharm Group an exclusive license to develop and commercialise FF284 in all countries worldwide including Japan. FF284, called Debio 1347 by Debiopharm, was discovered by Chugai and is about to start clinical development in oncology.

Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284. According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study.

Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Chugai News  
  Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent  (Jan 9, 2013)
  Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial  (Dec 16, 2008)
  DATA from Overseas Phase III Trial of "Actemra" a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients  (Oct 27, 2008)
  Roche to Raise Chugai Pharm Stake to 59.9 Percent  (May 23, 2008)
  Chugai Pharmaceutical Announcement of Supplemental Approval of Indication of Sigmart(R) Injection, a Treatment Drug for Unstable Angina Pectoris  (Oct 23, 2007)
  Chugai Pharmaceutical Announcement of Supplemental Approval of Indication of Sigmart(R) Injection, a Treatment Drug for Unstable Angina Pectoris  (Oct 23, 2007)
  Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva(R) Tablet Approved in Japan  (Oct 22, 2007)
  Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva(R) Tablet Approved in Japan  (Oct 22, 2007)
  Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin(R) Injection" for Treatment of Chemotherapy-Induced Anemia  (Sept 27, 2007)
  Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin(R) Injection" for Treatment of Chemotherapy-Induced Anemia  (Sept 27, 2007)



 Recent  Drugs & OTC News   
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)